BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/7/2020 1:14:54 PM | Browse: 1067 | Download: 2329
 |
Received |
|
2019-11-06 07:37 |
|
Peer-Review Started |
|
2019-11-05 09:41 |
|
First Decision by Editorial Office Director |
|
2019-12-07 04:23 |
|
Return for Revision |
|
2019-12-07 04:23 |
|
Revised |
|
2019-12-13 19:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-12-30 06:02 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-01-01 22:54 |
|
Articles in Press |
|
2020-01-01 22:54 |
|
Edit the Manuscript by Language Editor |
|
2020-01-13 19:27 |
|
Typeset the Manuscript |
|
2020-02-06 02:41 |
|
Publish the Manuscript Online |
|
2020-02-07 13:14 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Control Study |
| Article Title |
Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong Zheng, Jin-Jing Wang, Xiao-Rong Yang and Yong-Lin Yu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hong Zheng, PhD, Chief Physician, Department of Pathology, The Affiliated Hospital of Zunyi Medical University, No.149, Dalian Road, Zunyi 563003, Guizhou Province, China. z5tff9l3@sina.com |
| Key Words |
E2F transcription factor 1; MicroRNA 34c; Gastric cancer; Paclitaxel combined with cisplatin resistance; ; |
| Core Tip |
Gastric cancer (GC) is one of the most common types of cancer. The molecular mechanism of GC is intricate, and understanding the molecular mechanism of drug resistance is helpful to improve the effect of chemotherapy. The mutual binding of miRNAs and transcription factors is closely related to the occurrence of cancer. In this study, it was found that E2F transcription factor 1 inhibited the transcription of miR-34c to promote the proliferation of GC cells, and enhance the resistance of paclitaxel combined with cisplatin. While silencing the expression of E2F transcription factor 1 in GC cells could improve the efficacy of paclitaxel combined with cisplatin. |
| Publish Date |
2020-02-07 13:14 |
| Citation |
Zheng H, Wang JJ, Yang XR, Yu YL. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells. World J Gastroenterol 2020; 26(5): 499-513
|
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i5/499.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i5.499 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
